Southwark CCGs Medicines Optimisation Team’s Branded Generics Advice
Southwark CCGs Medicines Optimisation Team’s (MOT) QIPP 2018-2019 strategy includes the prescribing of branded generic medications for a small selection of medicines. We are emailing you to notify you of upcoming changes so that you can manage your stock in a controlled way.
The selected medicines which Southwark prescribers will be encouraged to prescribe as a particular branded generic is as follows:
1. Oxycodone modified-release tablets prescribed as Longtec® tablets
2. Oxycodone immediate release capsules prescribed as Shortec® capsules
3. Fentanyl patches prescribed as Mezolar Matrix® patches
4. Isosorbide mononitrate 60mg modified-release tablets prescribed as Chemydur 60XL® tablets
5. Buprenorphine patches prescribed as Reletrans® patches
In addition to the above we will also be encouraging our prescribers to carry out the following where appropriate:
1. Switch patients from Octasa® to Asacol®
2. Switch patients from dutasteride to finasteride
3. Switch patients from omeprazole gastro-resistant tablets to gastro-resistant capsules
The changes are taking effect in a gradual way as we are encouraging prescribers to consider individual patients when moving to the other product.
As the companies who manufacture branded generics tend to be small with limited manufacturing, the MOT have contacted each of the companies who manufacture the above branded generics for reassurance that they have stock for at least the next 12 months.
